Halozyme Therapeutics | HALO - Current Liabilities


Halozyme Therapeutics reported $363.21M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Baxter International USD 3.59B 102M Jun/2026
Cara Therapeutics USD 11.26M 216K Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
DBV Technologies USD 54.3M 2.5M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
MannKind USD 142.9M 8.34M Jun/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
United Therapeutics USD 607.8M 8.7M Jun/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025